secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2025-06-20T23:59:59+00:00
Accession:  0000950170-25-088168
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Galecto stockholders approve director elections, preferred stock conversion, and auditor ratification
--------------------------------------------------------------------------------

- Carl Goldfischer and David Shapiro elected as Class II directors with 219,253 and 226,360 votes for; 435,515 broker non-votes.
- Preferred stock conversion approved: 226,407 for, 15,099 against, 800 abstain; 435,515 broker non-votes.
- Ratification of EY as auditor approved: 660,974 for, 16,319 against, 528 abstain; no broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000095017025088168/0000950170-25-088168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000095017025088168/glto-20250618.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-088168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer